SCHEMBL6986036

SCHEMBL6986036

CC(C)[C@H](NS(=O)(=O)c1ccc(Cl)cc1)C(=O)ON1C(=O)CCC1=O

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 7/20 0.55
MMP9 P14780 7/20 0.55
MMP3 P08254 6/20 0.55
MMP13 P45452 6/20 0.55
MMP1 P03956 5/20 0.55
MMP7 P09237 5/20 0.55
SLC1A3 P43003 1/20 0.45
SLC1A2 P43004 1/20 0.45
SLC1A1 P43005 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 2/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 1/20 0.43
RECQL P46063 1/20 0.43
MMP8 P22894 2/20 0.43
MMP14 P50281 1/20 0.43
ADAMTS4 O75173 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3843452 0.88 MMP2 (0.55) MMP2MMP9MMP3MMP13MMP1
SCHEMBL6983496 0.88 MMP2 (0.55) MMP2MMP9MMP3MMP13MMP1
SCHEMBL6978976 0.82 SLC1A3 (0.49) MMP2MMP9MMP3MMP13MMP1
SCHEMBL6978444 0.75 MMP2 (0.91) MMP2MMP9MMP3MMP13MMP1
SCHEMBL8839521 0.75 MMP2 (0.91) MMP2MMP9MMP3MMP13MMP1
SCHEMBL27556946 0.73 MMP2 (0.60) MMP2MMP9MMP3MMP13MMP1
SCHEMBL13770429 0.72 MGLL (0.31) SLC1A2
SCHEMBL7408882 0.71 MMP2 (1.00) MMP2MMP9MMP3MMP13MMP1
SCHEMBL7408889 0.71 MMP2 (1.00) MMP2MMP9MMP3MMP13MMP1
SCHEMBL7351765 0.71 MMP9 (0.80) MMP2MMP9MMP3MMP13MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0927716-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-05-07 EP disclosed
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed